Often researched in combination treatments to overcome natural resistance mechanisms, more HDAC inhibitors, including Belinostat (approved for peripheral T-cell lymphoma) and experimental drugs like Entinostat (showing promise in breast cancer and non-small cell lung cancer), have expanded the therapeutic landscape 173,174. Here, HDAC9 is linked to peripheral T-cell lymphoma, not otherwise specified.